AbbVie EPS ABBV
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Sep 30, 2026
- $5.81
- Latest quarter, Q3 FY26
- $2.37
- +2270% on a year earlier
- Fiscal year 2025
- $2.36
- −2% on the year before
AbbVie's earnings per share was $5.81 over the twelve months to Sep 30, 2026, up 340% on a year earlier.
In its latest quarter, Q3 FY26, it was $2.37, up 2270% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 4% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.36 | −2% |
| FY2024 | $2.40 | −12% |
| FY2023 | $2.73 | −59% |
| FY2022 | $6.61 | +2% |
| FY2021 | $6.45 | +126% |
| FY2020 | $2.86 | −46% |
| FY2019 | $5.28 | +47% |
| FY2018 | $3.58 | +9% |
| FY2017 | $3.29 | −9% |
| FY2016 | $3.63 | +16% |
| FY2015 | $3.12 | +186% |
| FY2014 | $1.09 | −57% |
| FY2013 | $2.56 | −24% |
| FY2012 | $3.35 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $2.37 | +2270% | $5.81 | |
| Q2 FY26 | $2.03 | +290% | $3.54 | |
| Q1 FY26 | $0.39 | −46% | $2.03 | |
| Q4 FY25 | $1.02 | n/a | $2.36 | |
| Q3 FY25 | $0.10 | −89% | $1.32 | |
| Q2 FY25 | $0.52 | −32% | $2.10 | |
| Q1 FY25 | $0.72 | −6% | $2.35 | |
| Q4 FY24 | −$0.02 | −104% | $2.40 | |
| Q3 FY24 | $0.88 | −12% | $2.88 | |
| Q2 FY24 | $0.77 | −32% | $3.00 | |
| Q1 FY24 | $0.77 | +492% | $3.37 | |
| Q4 FY23 | $0.46 | −67% | $2.73 |
Against its peers
Companies in Drug Manufacturers - General nearest AbbVie's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ABBVAbbVie | $5.81 | +340% a year |
| JNJJohnson & Johnson | $6.60 | −36% a year |
| MRKMerck | $0.97 | −87% a year |
| AMGNAmgen | $16.09 | +32% a year |
| GILDGilead Sciences | −$3.16 | −149% a year |
| LLYEli Lilly and | $30.81 | +51% a year |
| PFEPfizer | $0.76 | −60% a year |
| BMYBristol-Myers Squibb | $4.51 | +52% a year |
| Peer median | $4.51 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on AbbVie
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.